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Cancers behave as organoids, composed not only by
genetically altered tumor cells, but also by a variety of
non-tumoral cells, such as fibroblasts, macrophages and
endothelial cells among others. Cellular interactions within
this organoid dictate the rate of tumor progression, and
therefore the accumulation of heterogeneous genotypes
which characterize the tumor mass at the moment of diag-
nosis. Evidence for both homotypic and heterotypic coop-
eration between cells within the tumor microenvironment
exist. We will show evidence for fluctuations in the
expression of a specific tumor marker, namely galectin-3.
Galectin-3 is an animal lectin that is found in diverse
cellular compartments, depending on the cellular context
and functional state of cells. Normal cells tend to accumu-
late galectin-3 in the nucleus. Upon malignant transforma-
tion, galectin-3 may concentrate in the cytoplasm and can
be secreted to the extracellular matrix, where it acts as a
matricellular protein, interfering with integrin function
among other cell surface glycoproteins. We had shown a
focal accumulation of galectin-3 in glioblastomas. Galec-
tin-3 expression was associated to a very specific tumor
microenvironment, the pseudopalisades- areas of viable
tumor cells surrounding necrotic areas that are commonly
found in advanced stages of glioblastomas. Galectin-3
expression in hypoxic and nutrient deprived cells is asso-
ciated the activation of HIF-1a and it was inhibitable by
NF-kB antagonists. In glioblastoma cells, galectin-3
expression was associated with its translocation to mito-
chondria, suggesting its involvement in mitochondrial
homeostasis. Inhibition of galectin-3 expression led to
increased cell death, indicating that galectin-3 acts as a
prosurvival factor in very specific tumor microenviron-
ments associated with glioblastoma progression. The pro-
tumoral role of galectin-3 was also observed in murine
melanomas, engrafted in both wild type and galectin-3-
deficient mice. Absence of galectin-3 from both tumoral
and stromal compartments was associated with attenuated
tumor growth, as compared to an experimental condition
where both tumor and stromal cells expressed galectin-3.
Intriguingly, de novo expression of galectin-3 was fre-
quently observed in tumors derived from cells that did not
express galectin-3 when these cells were engrafted in
galectin-3 deficient mice. This observation prompted us to
investigate whether galectin-3 expressing cells would favor
tumor growth when admixed with galectin-3 negative
cells. Indeed, when cells are admixed, tumors grew much
more efficiently than those engraftments of either cell
alone, indicating cooperation between galectin-3 expres-
sing cells and galectin-3 negative cells. Further experi-
ments indicated that galectin-3 expression is related with
the induction of a proangiogenic tumor environment.
Thus, targeting galectin-3 expression in selected tumors
may prove to be an effective strategy to control tumor
growth.
Angiogenesis and vasculature function are critically
altered in cancers, which are usually ill-perfused.
Evidence for activation of both angiotensin and bradykinin-
dependent pathways within the tumor microenvironment
of melanomas will be discussed. Blockage of vasoactive pep-
tide-dependent pathways may control tumor angiogenesis
and therefore may control tumor growth. Indeed, epide-
miological studies are now indicating that individuals
receiving specific blockers of angiotensin receptors may be
relatively protected from the development of tumors. In a
clinical setting, however, antiangiogenic drugs would be
preferably used in combination with chemotherapeutic
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drugs. Vasculature function, however is also critical for the
proper delivery of chemotherapeutic drugs to tumors,
specific therapeutic windows for the application of antian-
giogenic drugs need to be identified. This notion will be
further discussed. Altogether, the examples above call for a
necessary understanding of tumor physiology, which seems
to be under appreciated in the design of experimental/
clinical trials.
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